Stay updated on Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.
Latest updates to the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page
- Check7 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.2%
- Check14 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study, along with the location details.SummaryDifference1%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe website has added new completion dates for studies, including a completed status as of November 19, 2024, while several outdated statuses and options for data download have been removed.SummaryDifference2%
- Check43 days agoChange DetectedThe website has been updated to version v2.12.2, adding new features for downloading data in various formats and allowing users to select specific fields for export.SummaryDifference2%
- Check51 days agoChange DetectedThe website has been updated from version 2.12.0 to 2.12.1.SummaryDifference0.0%
- Check58 days agoChange DetectedThe website has been updated from version 2.11.2 to 2.12.0, indicating a new release with potential improvements or features.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.